Table 2.
Multivariate analysis of disease-free survival (DFS) and overall survival (OS) in 1.376 women with HER2-positive breast cancer
| B coefficients | Standard error | Wald | P | Hazard ratio | 95.0% confidence interval | |||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| DFS | ER + PR+ vs. ER-PR+ | .391 | .619 | .399 | 0.528 | 1.478 | .439 | 4.973 |
| ER + PR+ vs. ER-PR- | .394 | .261 | 2.284 | 0.131 | 1.483 | .890 | 2.471 | |
| ER + PR+ vs. ER + PR- | .457 | .388 | 1.389 | 0.239 | 1.580 | .738 | 3.382 | |
| ER-PR- vs. ER-PR+ | -.003 | .619 | .000 | 0.996 | .997 | .296 | 3.357 | |
| ER-PR- vs. ER + PR- | .064 | .373 | .029 | 0.864 | 1.066 | .513 | 2.214 | |
| OS | ER + PR+ vs. ER-PR+ | −7.587 | 82.200 | .009 | 0.926 | .001 | .000 | 4.71E + 66 |
| ER + PR+ vs. ER-PR- | 1.376 | .583 | 5.576 | 0.018 | 3.958 | 1.263 | 12.398 | |
| ER + PR+ vs. ER + PR- | .241 | 1.125 | .046 | 0.830 | 1.273 | .140 | 11.549 | |
| ER-PR- vs. ER-PR+ | −8.962 | 82.199 | .012 | 0.913 | .000 | .000 | 1.18E + 66 | |
| ER-PR- vs. ER + PR- | −1.135 | 1.036 | 1.200 | 0.273 | .322 | .042 | 2.449 | |
(Adjusted for age, stage, nuclear grade, Ki-67and trastuzumab treatment).